Linaclotide

Drug Profile

Linaclotide

Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MM-416775

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Microbia
  • Developer Allergan; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Oligopeptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation; Irritable bowel syndrome

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Preclinical Visceral pain

Most Recent Events

  • 09 Aug 2017 Chemical structure information added
  • 03 Aug 2017 Astellas plans to submit supplemental new drug application (sNDA) to Pharmaceuticals and Medical Devices Agency in Japan for Constipation in second half of 2017
  • 06 May 2017 Efficacy and adverse events data from a phase IIIb trial in Irritable bowel syndrome with constipation presented at the Digestive Disease Week 2017 (DDW - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top